CSIMarket
 
Cryoport inc   (NASDAQ: CYRX)
 
Price: $16.0000 $-0.09 -0.559%
Day's High: $16.059999465942383 Week Perf: -4.31 %
Day's Low: $ 15.77 30 Day Perf: 6.03 %
Volume (M): 478,784 52 Wk High: $ 17.20
Volume (M$): $ 0 52 Wk Avg: $11.25
Open: $15.92 52 Wk Low: $7.61



 Market Capitalization (Millions $) 798
 Shares Outstanding (Millions) 50
 Employees 738
 Revenues (TTM) (Millions $) 183
 Net Income (TTM) (Millions $) 72
 Cash Flow (TTM) (Millions $) 226
 Capital Exp. (TTM) (Millions $) 26

Business Description


We provide cryogenic logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and specialized cold chain logistics knowhow. We view our solutions as disruptive to the “older technologies” of dry ice and liquid nitrogen, in that our solutions are comprehensive and combine our competencies in configurations that are customized to our client’s requirements. We provide comprehensive, reliable, economic alternatives to all existing logistics solutions and services utilized for frozen shipping in the life sciences industry (e.g., personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). As part of our services we provide the ability to monitor, record and archive crucial information for each shipment that can be used for scientific and regulatory purposes.

Our Cryoport Express® Solutions include a sophisticated cloud-based logistics operating platform, which is branded as the Cryoportal™. The Cryoportal™ supports the management of the entire shipment and logistics process through a single interface, including initial order input, document preparation, customs clearance, courier management, shipment tracking, issue resolution, and delivery. In addition, it provides unique and incisive information dashboards and validation documentation for every shipment. The Cryoportal™ records and retains a fully documented “chain-of-custody” and, at the client’s option, “chain-of-condition” for every shipment, helping ensure that quality, safety, efficacy, and stability of shipped commodities are maintained throughout the process. This recorded and archived information allows our clients to meet exacting requirements necessary for scientific work and for proof of regulatory compliance during the logistics phase.

The branded packaging for our Cryoport Express® Solutions includes our liquid nitrogen dry vapor shippers, the Cryoport Express® Shippers. The Cryoport Express® Shippers are cost-effective and reusable cryogenic transport containers (our standard shipper is a patented vacuum flask) utilizing an innovative application of “dry vapor” liquid nitrogen (“LN2”) technology. Cryoport Express® Shippers are International Air Transport Association (“IATA”) certified and validated to maintain stable temperatures of minus 150° C and below for a 10-day dynamic shipment period. The Company currently features three Cryoport Express® Shippers: the Standard Dry Shipper (holding up to 75 2.0 ml vials), the High Volume Dry Shipper (holding up to 500 2.0 ml vials) and the recently introduced Cryoport Express® CXVC1 Shipper (holding up to 1,500 2.0 ml vials). In addition, we assist clients with internal secondary packaging (e.g., vials, canes, straws and plates).

Our most used solution is the “turnkey” solution, which can be accessed directly through our cloud-based Cryoportal™ or by contacting Cryoport Client Care for order entry. Once an order is placed and cleared, we ship a fully charged Cryoport Express® Shipper to the client who conveniently loads its frozen commodity into the inner chamber of the Cryoport Express® Shipper. The customer then closes the shipper package and reseals the shipping box displaying the next recipient’s address (“Flap A”) for pre-arranged carrier pick up. Cryoport arranges for the pick-up of the parcel by a shipping service provider, which is designated by the client or chosen by Cryoport, for delivery to the client’s intended recipient. The recipient simply opens the shipper package and removes the frozen commodity that has been shipped. The recipient then reseals the package, displaying the nearest Cryoport Staging Center address, making it ready for pre-arranged carrier pick-up. When the Cryoport Staging Center receives the Cryoport Express® Shipper, it is cleaned, put through quality assurance testing, and returned to inventory for reuse.


“Customer Staged Solution,” designed for clients making 50 or more shipments per month. Under this solution, we supply an inventory of our Cryoport Express® Shippers to our customer, in an uncharged state, enabling our customer (after training/certification) to charge them with liquid nitrogen and use our Cryoportal™ to enter orders with shipping and delivery service providers for the transportation of the package.

“Customer Managed Solution,” a limited customer implemented solution, whereby we supply our Cryoport Express® Shippers to clients in a fully charged state, but leaving it to the client to manage the shipping, including the selection of the shipping and delivery service provider and the return of the shipper to us.

“powered by CryoportSM,” available to providers of shipping and delivery services who seek to offer a “branded” cryogenic logistics solution as part of their service offerings, with “powered by CryoportSM” appearing prominently on the offering software interface and packaging. This solution can also be private labeled upon meeting certain requirements, such as minimum required shipping volumes.

“Integrated Solution,” which is our total outsource solution. It is our most comprehensive solution and involves our management of the entire cryogenic logistics process for our client, including Cryoport employees at the client’s site to manage the client’s cryogenic logistics function in total.

“Regenerative Medicine Point-of-Care Repository Solution,” designed for allogeneic therapies. In this solution we supply our Cryoport Express® Shipper to ship and store cryogenically preserved life science products for up to six days (or longer periods with supplementary shippers) at a point-of-care site, with the Cryoport Express® Shipper serving as a temporary freezer/repository enabling the efficient and effective distribution of temperature sensitive allogeneic cell-based therapies without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation device.

“Personalized Medicine and Cell-based Immunotherapy Solution,” designed for autologous therapies. In this solution our Cryoport Express® Shipper serves as an enabling technology for the safe transportation of manufactured autologous cellular-based immunotherapy market by providing a comprehensive logistics solution for the verified chain of custody and condition transport from, (a) the collection of the patient’s cells in a hospital setting, to (b) a central processing facility where they are manufactured into a personalized medicine, to (c) the safe, cryogenically preserved return of these irreplaceable cells to a point-of-care treatment facility. If required, the Cryoport Express® Shipper can then serve as a temporary freezer/repository to allow the efficient distribution of this personalized medicine to the patient when and where the medical provider needs it most without the expense, inconvenience, and potential costly failure of an on-sight, cryopreservation device.



   Company Address: 112 Westwood Place, Suite 350 Brentwood 37027 TN
   Company Phone Number: 470-2300   Stock Exchange / Ticker: NASDAQ CYRX


Customers Net Income fell by CYRX's Customers Net Profit Margin fell to

-39.02 %

13.98 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BLFS   -0.32%    
CRL   -3.46%    
TMO   -1.85%    
VEEV        14.98% 
• View Complete Report
   



Stocks on the Move

CryoPort Inc Turbulent Times and Investigative Claims Shake Shares, but Collaborative Partnerships Provide Hope

Published Fri, Jul 12 2024 11:30 AM UTC

CryoPort Inc: Turbulent Times and Investigative Claims Shake Shares, but Collaborative Partnerships Provide HopeCryoPort, Inc. (NASDAQ: CYRX) has witnessed a rollercoaster ride in its stock performance, facing significant sell-offs followed by a brief surge in share prices. Investors have raised concerns surrounding the company s financial health, as well as ongoing investig...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 10.13
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4.36
Price to Sales (Expected) -
Price to Book 1.61
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.8
Working Capital Ratio 2.1
Leverage Ratio (MRQ) 0.54
Total Debt to Equity 0
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 1.58 $
Revenues (TTM) 3.67 $
Cash Flow (TTM) 4.52 $
Cash 8.13 $
Book Value 9.92 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 247,879
Net Income per Employee (TTM) 97,206
Receivable Turnover Ratio (TTM) 5.2
Inventory Turnover Ratio (TTM) 4.23
Asset Turnover Ratio (TTM) 0.24

Profitability Ratios Current
Gross Margin (MRQ) 45.85 %
Operating Margin (MRQ) -20.11 %
Net Margin (MRQ) -26.24 %
Net Cash Flow Margin (MRQ) 46.9 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 9.33 %
Return On Investment (TTM) 11.16 %
Return On Equity (TTM) 14.16 %
Dividend Yield -
Pay out Ratio (TTM) -



Cryoport Inc's Segments
Foreign Customers    26.78 % of total Revenue
Life Sciences Services    58.4 % of total Revenue
BioLogistics Solutions    45.33 % of total Revenue
BioStorage BioServices    10.94 % of total Revenue
Life Sciences Products    43.64 % of total Revenue
Americas    73.14 % of total Revenue
Europe the Middle East and Africa EMEA    18.73 % of total Revenue
Asia Pacific APAC    8.14 % of total Revenue
segments    102.03 % of total Revenue
Interelimination    2.03 % of total Revenue
Interelimination Life Sciences Services    1 % of total Revenue
Interelimination Life Sciences Products    1.03 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.